双类似物鼻黏膜耐受对EAMG临床发病的抑制作用

目的　采用双类似物 (Lys2 6 2 Ala2 0 7)通过不同时间点对实验性自身免疫性重症肌无力 (EAMG)模型进行鼻黏膜耐受预防性给药 ,观察临床发病变化 ,并评价疗效 ,探讨其控制EAMG临床发病作用机制。方法　应用AChR加CFA致敏Lewis大鼠建立EAMG模型 ,并在致敏前 10天 (A组 )及致敏当日 (B组 )鼻腔给药。观察给药后A、B组及相应对照组大鼠体重、临床症状及肌电图变化。结果　①急性期和慢性期A、B组体重明显超过、而病情明显轻于相应对照组 ,慢性期A组体重明显超过、病情明显轻于B组 ,P均 <0 .0 5 ;②A、B组低频重复电刺激出现衰减反应D5阳性率明显低于相应对照组 ,P均 <0 .0 5。结论　Lys2 6 2 Ala2 0 7鼻黏膜预防耐受可有效地抑制临床发病 ,为采用双类似物鼻黏膜耐受防治人类重症肌无力提供了依据。

Effects of nasal tolerance with dual analogue on experimental autoimmune myasthenia gravis in Lewis rats

Objective To study the effect of nasal tolerance with a dual analogue (Lys262 Ala207) on experimental autoimmune myasthenia gravis (EAMG) and the underlying mechanisms,and to observe the clinical changes in Lewis rats treated with dual analogue nasally before or on the day of immunization.Methods To compare the effects of the predetermined dosage of dual analogue at different time points,dual analogues were given nasally before immunization for 10 consecutive days with acetylcholine receptor (AChR) in complete Freud's adjuvant (CFA).The body weight,clinical symptoms and CAMP were evaluated.Results Compared with the corresponding control groups,Lewis rats in group A or B were developed EAMG with increased weight and reduced severity and decremental D 5 positive rate of CAMP in acute and chronic phases( P <0.05).Conclusion Nasal administration with a dual analogue,Lys 262 Ala 207,at two different time points can ameliorate muscular weakness in EAMG rats. Thus,our results might give light to mucosal tolerance with dual analogue as an alternative maneuver in human MG.